Dual actions of 5‐MeO‐DIPT at the serotonin transporter and serotonin 5‐HT1A receptor in the mouse striatum and prefrontal cortex
Neuropsychopharmacology Reports February 6, 2021 Yoko Hagino, F. Scott Hall, George R. Uhl et al. 3 citations
The hallucinogenic tryptamine analogue 5-MeO-DIPT decreases extracellular serotonin in the striatum but not in the prefrontal cortex of mice. In mice lacking the serotonin transporter, 5-MeO-DIPT does not affect serotonin levels, indicating its action depends on that transporter. When a 5-HT1A receptor antagonist is present, 5-MeO-DIPT substantially increases serotonin, suggesting the drug's serotonin reuptake inhibition is masked by its concurrent activation of 5-HT1A receptors. 5-MeO-DIPT also dose-dependently increases extracellular dopamine in the prefrontal cortex regardless of serotonin transporter presence, an effect not blocked by the 5-HT1A antagonist. Thus, 5-MeO-DIPT dually acts on the serotonin transporter and 5-HT1A receptors, limiting serotonin elevation while independently raising dopamine in the prefrontal cortex.